Stock In Focus – TAM Stock Screener – AbbVie Inc (ABBV)
Thursday, August 3, 2023 · Johnny Hopkins
As part of our ongoing series here at The Acquirer’s Multiple, we provide this feature article titled ‘Stock in Focus‘ where we focus on one of the stocks from our Stock Screeners.
One of the cheapest stocks in our Stock Screeners is:
AbbVie Inc (ABBV)
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm’s top drug, Humira, represents close to half of the company’s current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women’s health.
A quick look at the share price history (below) over the past twelve months shows that the price is down 5.51%. Here’s why the company is undervalued.
Key Stats
Market Cap: $250.31 Billion
Enterprise Value: $305.71 Billion
Operating Earnings
Operating Earnings: $23.30 Billion
Acquirer’s Multiple
Acquirer’s Multiple: 13.10
Free Cash Flow (TTM)
Free Cash Flow: $23.52 Billion
FCF/EV Yield %:
FCF/EV Yield: 9.40
Shareholder Yield %:
Shareholder Yield: 4.80
Other Indicators
Piotroski F-Score: 5.00
Altman Z-Score: 2.104
ROA (5 Year Avge%): 17
Where Is the Deep Value in Canadian Stocks This Week?
Investing Beyond AI: Why Traditional Businesses Could Still Thrive
Undervalued Private Credit Investing: Finding Value in Discounted Lending Funds